Vistagen therapeutics
Social Anxiety Disorder. Based on the 2021 National Health and Wellness Survey, social anxiety disorder (SAD) affects over 25 million Americans, with onset typically in the mid-teens or earlier, and is diagnosed slightly more frequently in females than males. SAD can be viewed as a series of acute, socially stressful events in which patients ...Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ...
Did you know?
PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders.VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) ASSETS: Current assets: Cash and cash equivalents $ 51,986,400 $ 68,135,300 Prepaid expenses and other current assets 2,890,300 2,745,800
View VistaGen Therapeutics, Inc VTGN investment & stock information. Get the latest VistaGen Therapeutics, Inc VTGN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Vistagen Therapeutics, Inc. VTGN on Nasdaq · This company's Exchange Act registration has been revoked · This company's Exchange Act registration as a Municip...06 Jun 2023 ... VistaGen Therapeutics, Inc. (VTGN) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will ...Jun 23, 2022 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) March 31, March 31, 2022. 2021 ASSETS: Current assets: ... VistaGen Therapeutics. 1. How has your career led you to VistaGen, and why did you choose to move into CNS biopharmaceuticals? I am passionate about ...
Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive ...VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year 2024 Second Quarter ... ….
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Vistagen therapeutics. Possible cause: Not clear vistagen therapeutics.
The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...
EX-101.INS - XBRL INSTANCE DOCUMENT: Jun 30, 2020: 10-K: Annual report which provides a comprehensive overview of the company for the past yearVistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...
draw quick draw Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... tv plus gratisjcpenney en espanol ofertas PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ... what is bcc in email Prior to joining Vistagen as Chief Commercial Officer, Ms. Cunningham served as Managing Partner of i 3 Strategy Partners, where she guided senior pharmaceutical and biotechnology executives in planning and executing successful portfolio strategies and brand launches. Her experience in the pharmaceutical industry includes numerous instrumental ... grand canyon arizona maphttp zoom usparis france railway stations Vistagen’s fasedienol is an innovative, rapid-onset investigational pherine nasal spray in Phase 3 clinical development in the U.S. for the acute treatment of anxiety in adults with social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed mechanism of action (MOA) of fasedienol is novel and ... how do you call on private Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. allegient check instream practical magicwhere can i watch charlie brown christmas PH15 is an investigational pherine nasal spray with a novel, rapid-onset potential mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments to improve cognitive impairment caused by mental fatigue and potentially other disorders. Vistagen believes PH15 has the potential to improve ...Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.73 million. As a group, research analysts expect that Vistagen Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.